Blood Journal
Leading the way in experimental and clinical research in hematology

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA

  1. Richard Delarue1,
  2. Corinne Haioun2,
  3. Vincent Ribrag3,
  4. Pauline Brice4,
  5. Alain Delmer5,
  6. Herve Tilly6,
  7. Gilles Salles7,
  8. Achiel Van Hoof8,
  9. Olivier Casasnovas9,
  10. Nicole Brousse10,
  11. Francois Lefrere1, and
  12. Olivier Hermine1,*
  1. 1 Service d'hematologie, Hopital Necker, Paris, France;
  2. 2 Service d'hematologie, Hopital Henri Mondor, Creteil, France;
  3. 3 Service d'hematologie, Institut Gustave Roussy, Villejuif, France;
  4. 4 Service d'hematologie, Hopital Saint-Louis, Paris, France;
  5. 5 Service d'hematologie, Hopital Robert Debre, Reims, France;
  6. 6 Service d'hematologie, Centre Henri Becquerel, Rouen, France;
  7. 7 Service d'hematologie, Centre hospitalier Lyon Sud, Pierre-Benite, France;
  8. 8 Service d'hematologie, AZ St. Jan, Brugge, Belgium;
  9. 9 Service d'hematologie, Hopital du Bocage, Dijon, France;
  10. 10 Service d'anatomie pathologique, Hopital Necker, Paris, France
  1. * Corresponding author; email: ohermine{at}


Treatment of mantle cell lymphoma (MCL) in younger patients remains a challenge. We report results of a phase II trial using Cytarabine and Rituximab (R) as induction regimen before autologous stem cell transplantation (ASCT). Patients under 66y with stage III-IV, MCL were included. Treatment consisted in three courses of CHOP21 with Rituximab at the third one and three R-DHAP. Responding patients were eligible for ASCT with TAM6 or BEAM. Sixty patients were included. Median age was 57 years. Characteristics of patients were: BM involvement 85%, leukemic disease 48%, gastrointestinal involvement 52%, PS>1 6%, LDH>1N 38%, MIPI (low 55%, intermediate 38%, high 13%). ORR was 93% after (R)-CHOP and 95% after R-DHAP. Whereas CR was uncommon after (R)-CHOP (12%), high proportion of patients (57%) was in CR after R-DHAP. With median follow-up of 67 months, median EFS is 83 months and median OS is not reached. Five-year OS is 75%. Comparison with previous study without Rituximab (Lefrere et al., Haematologica 2007) shows improvement of outcome (median EFS: 51 versus 83 months). No toxic death or unexpected toxicities were observed. This study confirms that induction with Rituximab and Cytarabine-based regimens are safe and effective in MCL patients. This regimen is currently compared with R-CHOP21 induction in a multicentric European protocol.

  • Submitted September 21, 2011.
  • Accepted May 7, 2012.